Viking Therapeutics Stock (NASDAQ:VKTX)


ForecastChart

Previous Close

$30.70

52W Range

$18.92 - $81.73

50D Avg

$27.77

200D Avg

$38.77

Market Cap

$3.53B

Avg Vol (3M)

$3.67M

Beta

0.64

Div Yield

-

VKTX Company Profile


Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

45

IPO Date

Apr 28, 2015

Website

VKTX Performance


Latest Earnings Call Transcripts


Q2 22Jul 27, 22 | 7:35 PM
Q1 22Apr 27, 22 | 10:49 PM
Q4 21Feb 09, 22 | 9:29 PM

Peer Comparison


TickerCompany
TGTXTG Therapeutics, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
VSTMVerastem, Inc.
AXSMAxsome Therapeutics, Inc.
HEPAHepion Pharmaceuticals, Inc.